Verve Therapeutics, Inc. (NASDAQ:VERV) Given Consensus Recommendation of “Buy” by Analysts
Shares of Verve Therapeutics, Inc. (NASDAQ:VERV – Get Free Report) have earned an average rating of “Buy” from the six ratings firms that are covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have issued a report on the […]
Shares of Verve Therapeutics, Inc. (NASDAQ:VERV – Get Free Report) have earned an average rating of “Buy” from the six ratings firms that are covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have issued a report on the […]
